Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

Avalyn Pharma announced completion of target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis. The global, randomized, double-blinded, placebo-controlled trial is evaluating two doses of AP01 against placebo, with primary endpoint measuring change in lung function at 52 weeks. Topline data is expected in the second half of 2027.